Clinicopathologic variables | Total cohort | Patients treated with R-CHOP | ||||
---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||
p value | p value | HR (95% CI) | p value | p value | HR (95% CI) | |
Age | ||||||
 > 60 vs. ≤ 60 | 0.035 | 0.181 |  | 0.074 |  |  |
Sex | ||||||
 Male vs. female | 0.544 |  |  | 0.661 |  |  |
ECOG PS | ||||||
 ≥ 2 vs. < 2 | <0.001 | 0.010 | 3.717 (1.371–10.080) | < 0.001 | 0.031 | 3.286 (1.116–9.677) |
B symptoms | ||||||
 Present vs. absent | 0.049 | 0.807 |  | 0.112 |  |  |
Serum LDH | ||||||
 Elevated vs. normal | 0.003 | 0.328 |  | 0.033 | 0.319 |  |
IPI | ||||||
 3–5 vs. 0–2 | < 0.001 | 0.001 | 4.910 (1.888–12.767) | < 0.001 | 0.002 | 4.823 (1.763–13.191) |
Primary site | ||||||
 Extranodal vs. nodal | 0.488 |  |  | 0.523 |  |  |
Extranodal site | ||||||
 ≥ 2 vs. < 2 | < 0.001 | 0.649 |  | 0.001 | 0.978 |  |
Bone marrow involvement | ||||||
 Present vs. absent | 0.308 |  |  | 0.359 |  |  |
Bulky mass | ||||||
 ≥ 10 cm vs. < 10 cm | 0.136 |  |  | 0.048 | 0.010 | 4.664 (1.449–15.017) |
Ann Arbor stage | ||||||
 III–IV vs. I–II | < 0.001 | 0.682 |  | < 0.001 | 0.812 |  |
Hans classification | ||||||
 Non-GCB vs. GCB | 0.075 |  |  | 0.135 |  |  |
Treatment regimen | ||||||
 RCHOP vs. other | 0.676 |  |  | – |  |  |
BCL2 expression | ||||||
 Positive vs. negative | 0.391 |  |  | 0.699 |  |  |
BCL6 expression | ||||||
 Positive vs. negative | 0.247 |  |  | 0.545 |  |  |
CD10 expression | ||||||
 Positive vs. negative | 0.543 |  |  | 0.778 |  |  |
MUM1 expression | ||||||
 Positive vs. negative | 0.138 |  |  | 0.211 |  |  |
PD-L1 tumor cell expression | ||||||
 Positive vs. negative | 0.400 |  |  | 0.353 |  |  |
PD-L1 immune cell expression | ||||||
 Positive vs. negative | 0.187 |  |  | 0.146 |  |  |
PD-L1 gene alteration | ||||||
 Present vs. absent | 0.900 |  |  | 0.871 |  |  |
pSTAT3 expression (> 40%) | ||||||
 Positive vs. negative | 0.021 | 0.017 | 2.724 (1.196–6.204) | 0.015 | 0.007 | 3.510 (1.418–8.692) |